A Pilot Phase 1 Study of Intrathecal Pemetrexed for Refractory Leptomeningeal Metastases From Non-small-cell Lung Cancer
Conclusion: Pemetrexed was appropriate for intrathecal administration. IP at 10 mg dose in combination with vitamin supplementation on the schedule of 1-2 times per week showed controllable toxicity and good efficacy. This regimen paves the way for subsequent clinical trial.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Alimta | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Folic Acid | Lung Cancer | Neoplastic Meningitis | Non-Small Cell Lung Cancer | Study | Toxicology | Vitamin B12 | Vitamin B9 | Vitamins